Before embarking on his entrepreneurial journey with a biotech startup, Anindya Roy arrived in the U.S. with just two suitcases and $2,000 to his name. Growing up in rural India without basic amenities like electricity and running water, Roy’s love for science drove him to pursue degrees at prestigious institutions such as the University of Calcutta and the Indian Institute of Technology in Kharagpur.
In 2008, Roy took a bold step by pursuing a Ph.D. at Arizona State University, which eventually led to a postdoctoral fellowship with Nobel Prize-winning chemist David Baker at the University of Washington. In 2023, Roy co-founded Lila Biologics in Seattle, utilizing AI-powered protein design technology developed in Baker’s lab to advance cutting-edge medical treatments.
Described as a brilliant and determined scientist by colleagues, Roy’s work in protein engineering for sustainable energy resources paved the way for his transition into the field of medicine. Through collaborations with industry leaders like Eli Lilly, Lila Biologics has made significant strides in developing therapeutic proteins for targeted radiotherapy and long-acting injectable drugs.
Roy’s unwavering dedication to scientific innovation is evident in his commitment to advancing the field of de novo protein design. Despite concerns about potential cuts to federal funding for research, Roy remains optimistic about the future of biotechnology and the limitless possibilities offered by evolving technology.
